Prevalence and Impact of COVID-19 in Immuno-compromised Individuals: An Experience from a Private Outpatient Setting of South Punjab, Pakistan
Abstract
To find out the prevalence and impact of COVID-19 on immunocompromised patients visiting outpatient department of a private healthcare facility of South Punjab, Pakistan.
This cross-sectional study was done at Outpatient Department of Aleena Hospital, Bahawalpur, Pakistan from 1st June 2020 to 30th December 2020. We included a total of 197 patients of both genders aged between 15 to 90 years visiting outpatient department of Aleena Hospital for various medical reasons. All patients underwent antibody testing for COVID-19 adopting immunochromatography for both IgG and IgM. A patient was labeled as immunocompromised if having diabetes mellitus or liver cirrhosis.
In a total of 197 patients, 122 (61.9%) were male. Overall, mean age was 45.1±13.3 years ranging 15 to 90 years. A total of 50 (25.4%) cases were antibody positive for COVID-19. BMI ≥ 25 (p=0.045), and “been to close proximity with someone who travelled outside/inside the country” (p=0.014) were noted to have significant association with COVID-19 positive cases while all other variables had insignificant association (p>0.05). Presence of diabetes mellitus was noted to have significant association with COVID-19 antibody positivity (p=0.002). Overall, no significant association of immunocompromised status and COVID-19 antibodies positivity was observed (p=0.090).
Prevalence of positive COVID-19 antibodies was very high among patients visiting outpatient department of a private healthcare setting of South Punjab, Pakistan. Immunocompromised individuals were not found to have any significant association with COVID-19 infections.
How to Cite This Article
Ali QM, Imran A, Shafique S, Khan R, Ullah HMK, Sohail S, et al.. Prevalence and Impact of COVID-19 in Immuno-compromised Individuals: An Experience from a Private Outpatient Setting of South Punjab, Pakistan. J Pak Soc Intern Med. 2022;3(2):117–120. doi:10.70302/jpsim.v3i2.2222
Conflict of Interest
All authors declare no competing interests.
Funding
No specific funding was received for this research.
Funder information follows the Crossref Funder Registry standard.
References
- Organization W.H. WHO Coronavirus disease (COVID-19) dashboard. [Updated 2020, cited 2022] Available from: [https://covid19.who.int/]
- Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, Wang Y. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020;99(9):47-56.
- Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Clin Infect Dis. 2020;71(16):2199-206.
- Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: Current state of the science. Immunity. 2020;52(6):910-41.
- Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-768.
- Anirvan P, Bharali P, Gogoi M, Thuluvath PJ, Singh SP, Satapathy SK. Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome - what we know so far. World J Hepatol. 2020;12(12):1182-97.
- Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martinez-Colon GJ, McKechnie JL, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26(7):1070-6.
- Urra JM, Cabrera CM, Porras L, Ródenas I. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients. Clin Immunol. 2020; doi:10.1016/j.clim.2020.108486 doi:10.1016/j.clim.2020.108486
- Goldman JD, Robinson PC, Uldrick TS, Ljungman P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer. 2021;9(6):e002630.
- Ahmed O, Asghar M, Khurshaidi M, Yasmin F, Kanwal N, Khokher AJ, et al. Provision of surgical services to COVID-19-infected patients at a tertiary care center in Pakistan: A one-year clinical review of the year 2020 in general surgery department. Cureus. 2021;13(1): e12705.
- Vaid N, Ardissino M, Reed TA, Goodall J, Utting P, Miscampbell M, et al. Clinical characteristics and outcomes of immunosuppressed patients hospitalized with COVID-19: experience from London. J Intern Med. 2021;289(3):385-94.
- Baek MS, Lee MT, Kim WY, Choi JC, Jung SY. COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea. PLoS One. 2021;16(10): e025764.
- Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020; doi: 10.1136/bmj.m3249 doi:10.1136/bmj.m3249
- Ferrari A, Zecca M, Rizzari C, Porta F, Provenzi M, Marinoni M, et al. Children with cancer in the time of COVID-19: An 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy. Pediatr Blood Cancer. 2020;67(8):e28410.
- Millen GC, Arnold R, Cazier JB, Curley H, Feltbower RG, Gamble A, et al. Severity of COVID-19 in children with cancer: Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project. Br J Cancer. 2021;124(4):754-9.
- Chan KH, Lee PW, Chan CY, Lam KBH, Ho PL. Monitoring respiratory infections in covid-19 epidemics. BMJ. 2020; doi: 10.1136/bmj.m1628 doi:10.1136/bmj.m1628
- Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res ClinPract. 2020; doi:10.1016/j.diabres.2020.108347 doi:10.1016/j.diabres.2020.108347
- Nassar M, Daoud A, Nso N, Medina L, Ghernautan V, Bhangoo H, et al. Diabetes mellitus and COVID-19: Review article. Diabetes MetabSyndr. 2021;15(6):102268.
- Shoaib N, Noureen N, Munir R, Shah FA, Ishtiaq N, Jamil N, et al. COVID-19 severity: Studying the clinical and demographic risk factors for adverse outcomes. PLoS One. 2021;16(8):e0255999.
Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.